# A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Source: https://onco.cc/trials/nct05316688/  
OnCo record `nct05316688` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tozuleristide run by University of Washington, terminated.

## Summary

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery is a phase 1/2 interventional study registered as NCT05316688 by University of Washington, with 8 participants enrolled, started 2024-04-17. Conditions recorded: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8 and Stage IVA Lip and Oral Cavity Cancer AJCC v8. Interventions recorded: Near Infrared Imaging, Therapeutic Conventional Surgery and Tozuleristide.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05316688
- Phase: 1/2
- Setting: Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent
- Sponsor: University of Washington
- Enrolled: 8

## Sources

- ClinicalTrials.gov NCT05316688: https://clinicaltrials.gov/study/NCT05316688

## Connected records

- cancers: [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/)
- drugs: [Tozuleristide](https://onco.cc/drugs/blz-100/)
- companies: [Blaze Bioscience](https://onco.cc/companies/blaze-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct05316688.json